Literature DB >> 21700447

Malignant peripheral nerve sheath tumours in NF1: improved survival in women and in recent years.

Sarah Ingham1, Susan M Huson, Anthony Moran, James Wylie, Michael Leahy, D Gareth R Evans.   

Abstract

BACKGROUND: Malignant peripheral nerve sheath tumours (MPNST) are the main soft tissue malignancy associated with neurofibromatosis 1. These uncommon tumours are known to occur at high frequency and lead to poor survival. Our aim was to determine risk of MPNST in NF1 patients, and survival rates.
METHODS: The incidence of MPNST in NF1 was identified through the NF1 genetic register and The North West Cancer Intelligence Service (NWCIS). Data were used to generate incidence and survival curves. Strict regional boundaries were adhered to avoid ascertainment bias. Kaplan-Meier curves were used to determine five and ten-year survival.
RESULTS: Of the 1059 NF1 patients 52 developed MPNST (30 cases in females and 22 in males), 43 cases were resident within the strict regional boundary. The risk of MPNST was 10.2% in males and 12.7% in females by age 70 years (p=0.9), with a statistically better survival in females than males (5 and 10 year survival 46% and 41.5% versus 22% and 8.2%; p=0.05). Survival was also significantly improved for patients diagnosed in the last 14 years compared to the previous 13-year period (p=0.03).
CONCLUSION: With fifteen strict regional MPNSTs in the fourteen years since our previous population study an annual incidence of above 1 per 1000 NF1 patients has now been maintained over a 27-year period. No significant increase in risk of MPNST in females compared to males was found, though the difference in survival is intriguing. Male survival is particularly poor with <10% alive at 10 years.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21700447     DOI: 10.1016/j.ejca.2011.05.031

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  The effect of estradiol, testosterone, and human chorionic gonadotropin on the proliferation of Schwann cells with NF1 +/- or NF1 -/- genotype derived from human cutaneous neurofibromas.

Authors:  Paula Pennanen; Sirkku Peltonen; Roope A Kallionpää; Juha Peltonen
Journal:  Mol Cell Biochem       Date:  2017-11-28       Impact factor: 3.396

2.  Pediatric and adult malignant peripheral nerve sheath tumors: an analysis of data from the surveillance, epidemiology, and end results program.

Authors:  E Susan Amirian; J Clay Goodman; Pamela New; Michael E Scheurer
Journal:  J Neurooncol       Date:  2014-01-05       Impact factor: 4.130

Review 3.  CNS Tumors in Neurofibromatosis.

Authors:  Jian Campian; David H Gutmann
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

4.  Clinical Outcome After Pencil Beam Scanning Proton Therapy of Patients With Non-Metastatic Malignant and Benign Peripheral Nerve Sheath Tumors.

Authors:  Nicolas Bachmann; Dominic Leiser; Alessia Pica; Barbara Bachtiary; Damien C Weber
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

Review 5.  Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.

Authors:  Matthias Kolberg; Maren Høland; Trude H Agesen; Helge R Brekke; Knut Liestøl; Kirsten S Hall; Fredrik Mertens; Piero Picci; Sigbjørn Smeland; Ragnhild A Lothe
Journal:  Neuro Oncol       Date:  2012-11-15       Impact factor: 12.300

6.  Gender dimorphism and age of onset in malignant peripheral nerve sheath tumor preclinical models and human patients.

Authors:  Elizabeth Shurell; Linh M Tran; Jonathan Nakashima; Kathleen B Smith; Brenna M Tam; Yunfeng Li; Sarah M Dry; Noah Federman; William D Tap; Hong Wu; Fritz C Eilber
Journal:  BMC Cancer       Date:  2014-11-15       Impact factor: 4.430

7.  Malignant peripheral nerve sheath tumours in inherited disease.

Authors:  D Gareth R Evans; Susan M Huson; Jillian M Birch
Journal:  Clin Sarcoma Res       Date:  2012-10-04

8.  Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.

Authors:  Jacqueline D Peacock; David Cherba; Kevin Kampfschulte; Mallory K Smith; Noel R Monks; Craig P Webb; Matthew Steensma
Journal:  J Transl Med       Date:  2013-09-17       Impact factor: 5.531

Review 9.  Cutaneous neurofibromas in the genomics era: current understanding and open questions.

Authors:  Robert J Allaway; Sara J C Gosline; Salvatore La Rosa; Pamela Knight; Annette Bakker; Justin Guinney; Lu Q Le
Journal:  Br J Cancer       Date:  2018-04-26       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.